Tag Archives: c-Met inhibitors

Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group.

Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group. Throughout the world Discovery Analysis, Cephalon, Inc. 145 Brandywine Parkway, West Chester, PA 19380-4245, USA. Abstract The hepatocyte growth aspect (HGF)-c-Met signaling axis is concerned in … Continue reading

Posted in Uncategorized | Tagged | Leave a comment